{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:45:38Z","timestamp":1780058738934,"version":"3.54.0"},"reference-count":66,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune condition related to autoantibodies against certain proteins in the postsynaptic membranes in the neuromuscular junction. This disorder has a multifactorial inheritance. The connection between environmental and genetic factors can be established by epigenetic factors, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). XLOC_003810, SNHG16, IFNG-AS1, and MALAT-1 are among the lncRNAs with a possible role in the pathoetiology of MG. Moreover, miR-150-5p, miR-155, miR-146a-5p, miR-20b, miR-21-5p, miR-126, let-7a-5p, and let-7f-5p are among miRNAs whose roles in the pathogenesis of MG has been assessed. In the current review, we summarize the impact of miRNAs and lncRNAs in the development or progression of MG.<\/jats:p>","DOI":"10.3390\/ijms222312964","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T22:01:11Z","timestamp":1638309671000},"page":"12964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-499X","authenticated-orcid":false,"given":"Soudeh","family":"Ghafouri-Fard","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 19835-35511, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Azimi","sequence":"additional","affiliation":[{"name":"Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran 19835-35511, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-6527","authenticated-orcid":false,"given":"Bashdar Mahmud","family":"Hussen","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-0591","authenticated-orcid":false,"given":"Mohammad","family":"Taheri","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, Jena University Hospital, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Jalili Khoshnoud","sequence":"additional","affiliation":[{"name":"Functional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran 19835-35511, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis\u2014Pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaut.2013.12.001","article-title":"Genetic basis of myasthenia gravis\u2014A comprehensive review","volume":"52","author":"Avidan","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"404053","DOI":"10.1155\/2013\/404053","article-title":"Recent Advances in Genetic Predisposition of Myasthenia Gravis","volume":"2013","author":"Zagoriti","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wang, W., Zhu, W., Dong, J., Cheng, Y., Yin, Z., and Shen, F. (2019). Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225573"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e12886","DOI":"10.1111\/sji.12886","article-title":"LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1\/PD-L1 expression in patients with myasthenia gravis-related thymoma","volume":"92","author":"Hu","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/1440-1681.13280","article-title":"LncRNA XLOC_003810 modulates thymic Th17\/Treg balance in myasthenia gravis with thymoma","volume":"47","author":"Niu","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.omtn.2020.01.005","article-title":"Identification of the regulatory role of lncRNA SNHG16 in myasthenia gravis by constructing a competing endogenous RNA network","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2017.08.008","article-title":"IFNA-AS1 regulates CD4 + T cell activation in myasthenia gravis though HLA-DRB1","volume":"183","author":"Luo","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1002\/jcb.27838","article-title":"The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis","volume":"120","author":"Kong","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2016.09.005","article-title":"Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients","volume":"299","author":"Zhang","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Luo, Z., Li, Y., Liu, X., Luo, M., Xu, L., Luo, Y., Xiao, B., and Yang, H. (2015). Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes. BMC Med. Genom., 8.","DOI":"10.1186\/s12920-015-0087-z"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1038\/s41598-020-68185-x","article-title":"AChR antibodies show a complex interaction with human skeletal muscle cells in a transcriptomic study","volume":"10","author":"Hong","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e23722","DOI":"10.1002\/jcla.23722","article-title":"Expression profiling and bioinformatics analysis of exosomal long noncoding RNAs in patients with myasthenia gravis by RNA sequencing","volume":"35","author":"Lu","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41598-021-81962-6","article-title":"Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis","volume":"11","author":"Bo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3892\/ijmm.2017.2853","article-title":"Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis","volume":"39","author":"Cao","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13023-020-01629-9","article-title":"Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis","volume":"15","author":"Europa","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, L., Wang, J., Sun, X., Cao, Y., Ning, S., Zhang, H., Chen, L., Li, R., Tian, Q., and Wang, L. (2014). Identifying a Polymorphic \u2018Switch\u2019 That Influences miRNAs\u2019 Regulation of a Myasthenia Gravis Risk Pathway. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104827"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.21037\/gs-20-39","article-title":"Signaling pathways of genetic variants and miRNAs in the pathogenesis of myasthenia gravis","volume":"9","author":"Qian","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104388","DOI":"10.1016\/j.phrs.2019.104388","article-title":"MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine","volume":"148","author":"Cavalcante","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1","volume":"33","author":"Cheng","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"724715","DOI":"10.1155\/2015\/724715","article-title":"Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis","volume":"2015","author":"Cao","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sengupta, M., Wang, B.-D., Lee, N.H., Marx, A., Kusner, L.L., and Kaminski, H.J. (2018). MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205464"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2018.01.008","article-title":"Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues","volume":"17","author":"Cron","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.07.003","article-title":"Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells","volume":"14","author":"Jiang","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.imlet.2016.02.005","article-title":"Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells","volume":"172","author":"Li","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.03.021","article-title":"miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells","volume":"320","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nogales-Gadea, G., Ramos-Fransi, A., Su\u00e1rez-Calvet, X., Navas, M., Rojas-Garc\u00eda, R., Mosquera, J.L., Diaz-Manera, J., Querol, L., Gallardo, E., and Illa, I. (2014). Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091927"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11481-013-9498-9","article-title":"Identification of Novel MicroRNA Signatures Linked to Experimental Autoimmune Myasthenia Gravis Pathogenesis: Down-Regulated miR-145 Promotes Pathogenetic Th17 Cell Response","volume":"8","author":"Wang","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021037369","article-title":"Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies","volume":"31","author":"Tan","year":"2021","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis","volume":"292","author":"Punga","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2018.10.003","article-title":"Circulating microRNA plasma profile in MuSK plus myasthenia gravis","volume":"325","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"518942","DOI":"10.1155\/2014\/518942","article-title":"Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum","volume":"2014","author":"Jiang","year":"2014","journal-title":"Evid. -Based Complement. Altern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mus.26785","article-title":"Plasma exosomal miR-106a-5p expression in myasthenia gravis","volume":"61","author":"Xu","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.12659\/MSM.893458","article-title":"miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice","volume":"21","author":"Liu","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","article-title":"MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10","volume":"164","author":"Liu","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2015.08.013","article-title":"Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomas","volume":"288","author":"Wang","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/ecn.2015.0367","article-title":"Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients","volume":"26","author":"ChunJie","year":"2015","journal-title":"Eur. Cytokine Netw."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Huang, P., He, X.-Y., and Xu, M. (2021). Expression and Significance of MicroRNA-126 and MicroRNA-21 in Peripheral Blood Mononuclear Cells in Patients with Myasthenia Gravis. Neuroimmunomodulation, 1\u20138.","DOI":"10.1159\/000510714"},{"key":"ref_48","first-page":"213","article-title":"Altered expression and clinical significance of plasma circulating microRNA-23b in patients with myasthnia gravis","volume":"50","author":"Zhou","year":"2017","journal-title":"Chin. J. Neurol."},{"key":"ref_49","first-page":"302","article-title":"Altered expression of microRNA-27a-3p in the thymus tissue of patients with myasthenia gravis","volume":"49","author":"Li","year":"2016","journal-title":"Chin. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12974-020-01958-3","article-title":"Decreased expression of miR-29 family associated with autoimmune myasthenia gravis","volume":"17","author":"Cron","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cbin.11676","article-title":"Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133\/PAX7","volume":"45","author":"Lai","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2020.00142","article-title":"miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids","volume":"11","author":"Bortone","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5573469","DOI":"10.1155\/2021\/5573469","article-title":"Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum","volume":"2021","author":"Yan","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1166\/jbt.2019.2189","article-title":"The Expression of miRNA-146a in Peripheral Blood Mononuclear Cells of Patients with Myasthenia Gravis and Its Bioinformatics Analysis","volume":"9","author":"Huang","year":"2019","journal-title":"J. Biomater. Tissue Eng."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis","volume":"555","author":"Lu","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"577383","DOI":"10.1016\/j.jneuroim.2020.577383","article-title":"Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients","volume":"348","author":"Zhong","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5507\/bp.2019.009","article-title":"Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10","volume":"164","author":"Ao","year":"2020","journal-title":"Biomed. Pap."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mus.27233","article-title":"Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody","volume":"63","author":"Zhou","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_63","first-page":"777","article-title":"Role of miR-155 in myasthenia gravis and effect of dexamethasone on miR-155","volume":"37","author":"Chen","year":"2012","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/cei.12265","article-title":"Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis","volume":"176","author":"Wang","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","article-title":"Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis","volume":"16","author":"Zhang","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10616-021-00472-5","article-title":"MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells","volume":"73","author":"Lu","year":"2021","journal-title":"Cytotechnology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:55Z","timestamp":1760168275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":66,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222312964"],"URL":"https:\/\/doi.org\/10.3390\/ijms222312964","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}